Abstract
Evaluate real-world relative dose intensity (RDI) and drug holiday RDI in patients with locally advanced or metastatic breast cancer treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) (ribociclib, palbociclib or abemaciclib).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
